Clinical Trial Update: Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating CHR-2845 for safety and tolerability in hematological diseases and lymphoid malignancies. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Diseases
• Lymphoid Malignancies

Drugs mentioned

• CHR-2845

Snippet

Sponsor: Chroma Therapeutics | Conditions: Hematological Disease, Lymphoid Malignancies | Phase 1 | Status: COMPLETED